[1] Mehta K,Van Thiel DH,Shah N,et al. Nonalcoholic fatty liver disease：pathogenesis and the role of antioxidants. Nutr Rev,2002,60（9）：289-293.
[2] 谭彦芳,赵彩彦. 非酒精性脂肪肝药物治疗进展. 实用肝脏病杂志,2013,16（4）：378-381.
[3] 马雄,魏珏. 非酒精性脂肪肝伴发纤维化的研究现状.药品评价,2007,4（4）：282-283.
[4] 中华医学会肝脏病学会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志,2006,14（3）：161-163.
[5] 曹荣,胡旭东,柏涛,等. 熊去氧胆酸与牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较.中国药房,2013,24（4）：365-367.
[6] 张忠勇,祁月英,苏秀海,等. 非酒精性脂肪肝治疗研究进展.现代中西医结合杂志,2012,21（8）：902.
[7] Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep,2002,4：37-42.
[8] 张晓峰,王立福,白云峰,等. 泽泻联合熊去氧胆酸胶囊治疗非酒精性单纯性脂肪肝疗效观察. 中华中医药学刊,2012,30（2）：274.
[9] Tsukahara K,Kanai S,Ohta M,et al. Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats.Liver,1993,13：262-269.
[10] Heuman DM,Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology,1994,106：1333-1341.
[11] 王丹,杨玲,黄金明,等. 牛磺熊去氧胆酸抑制四氯化碳诱导的大鼠肝纤维化. 世界华人消化杂志,2010,18（19）：1979-1980.
[12] Crosignani A,Budillon G,Cimino L,et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis：a multicenter placebo-controlled study. Hepatogastroenterology,1998,45：1624-1629. |
